Shereen Paramalingam1,2, Merrilee Needham3,4,5,6, Sarah Harris7,8, Susan O'Hanlon9, Frank Mastaglia6, Helen Keen10. 1. University of Notre Dame Australia, Fremantle, WA, Australia. shereen.paramalingam@health.wa.gov.au. 2. Department of Rheumatology, Fiona Stanley Hospital, 11 Robin Warren Dr, Murdoch, WA, 6150, Australia. shereen.paramalingam@health.wa.gov.au. 3. University of Notre Dame Australia, Fremantle, WA, Australia. 4. Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, WA, Australia. 5. Department of Neurology, Fiona Stanley Hospital, Murdoch, WA, Australia. 6. Perron Institute for Neurological and Translational Science, University of Western Australia, Crawley, Australia. 7. Institute for Health Research, Notre Dame Australia, Fremantle, WA, Australia. 8. Western Australian Health Translation Network (WAHTN), Bentley, WA, Australia. 9. Department of Radiology, Fiona Stanley Hospital, Murdoch, WA, Australia. 10. Department of Rheumatology, Fiona Stanley Hospital, 11 Robin Warren Dr, Murdoch, WA, 6150, Australia.
Correction to: BMC Rheumatology (2022) 6:47. 10.1186/s41927-022-00276-w
Following publication of the original article [1], it was reported that there was an error in the caption for Fig. 1A.The caption previously read: “Fig. 1A US image showing patchy mild changes in echogenicity with hypoechoic areas and corresponding subcutaneous echogenicity in the vastus lateralis (cross-section) in a 26-year-old with Anti-NXP2.”The correct caption is: “Fig. 1A Mild increased echogenicity in the vastus lateralis (cross section) and subcutaneous tissue with patches of hypoechogenicity in a 26-year-old with Anti-NXP2 DM.”The article also contained several typographical errors, which have been corrected.The original article [1] has been updated.